Pharmacogenomics of Clopidogrel
Pharmacogenomics of Clopidogrel
In "Handbook of Pharmacogenomics and stratified medicine" (edited by Sandosh Padmanabhan of the University of Glasgow, UK), the Chapter 25 "Pharmacogenomics of clopidogrel" (by Betti Giusti, Claudia Saracini, Silvia Galora, Rossella Marcucci) addresses the state of the art for this issue.
- University of Florence Italy
Acute coronary syndrome; Antiplatelet therapy; Cardiovascular disease; Clopidogrel; Coronary artery disease; CYP2C19; Drug resistance; Fenetic testing; Major adverse cardiovascular events; Personalized medicine; Pharmacogenetics; Platelet; Platelet aggregation; Polymorphisms; Thrombosis; Medicine (all); Pharmacology, Toxicology and Pharmaceutics (all)
Acute coronary syndrome; Antiplatelet therapy; Cardiovascular disease; Clopidogrel; Coronary artery disease; CYP2C19; Drug resistance; Fenetic testing; Major adverse cardiovascular events; Personalized medicine; Pharmacogenetics; Platelet; Platelet aggregation; Polymorphisms; Thrombosis; Medicine (all); Pharmacology, Toxicology and Pharmaceutics (all)
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).1 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!